Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study.

Nowell WB, Curtis JR, Nolot SK, Curtis D, Venkatachalam S, Owensby JK, Poon JL, Calvin AB, Kannowski CL, Faries DE, Gavigan K, Haynes VS.

JMIR Res Protoc. 2019 Sep 26;8(9):e14665. doi: 10.2196/14665.

2.

The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures.

Sietsema DL, Araujo AB, Wang L, Boytsov NN, Pandya SA, Haynes VS, Faries DE, Taylor KA, Baser O, Jones CB.

J Bone Joint Surg Am. 2018 Nov 7;100(21):1819-1828. doi: 10.2106/JBJS.17.01388.

PMID:
30399076
3.

Application and comparison of generalized propensity score matching versus pairwise propensity score matching.

Cui ZL, Hess LM, Goodloe R, Faries D.

J Comp Eff Res. 2018 Sep;7(9):923-934. doi: 10.2217/cer-2018-0030. Epub 2018 Jun 21.

PMID:
29925271
4.

Addressing unmeasured confounding in comparative observational research.

Zhang X, Faries DE, Li H, Stamey JD, Imbens GW.

Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):373-382. doi: 10.1002/pds.4394. Epub 2018 Jan 30. Review.

PMID:
29383840
5.

Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.

Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI.

Curr Med Res Opin. 2018 Apr;34(4):619-632. doi: 10.1080/03007995.2017.1421918. Epub 2018 Feb 5.

PMID:
29298540
6.

Evaluating different strategies for estimating treatment effects in observational studies.

Zagar AJ, Kadziola Z, Lipkovich I, Faries DE.

J Biopharm Stat. 2017;27(3):535-553. doi: 10.1080/10543406.2017.1289953. Epub 2017 Feb 7.

PMID:
28282261
9.

Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.

Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY; Treatment With Adenosine Diphosphate Receptor Inhibitors–Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Investigators.

JAMA Cardiol. 2016 Sep 1;1(6):655-65. doi: 10.1001/jamacardio.2016.1783.

PMID:
27438179
10.

"A Bayesian sensitivity analysis to evaluate the impact of unmeasured confounding with external data: a real world comparative effectiveness study in osteoporosis".

Zhang X, Faries DE, Boytsov N, Stamey JD, Seaman JW Jr.

Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):982-92. doi: 10.1002/pds.4053. Epub 2016 Jul 11.

PMID:
27396534
11.

Covariates of depression and high utilizers of healthcare: Impact on resource use and costs.

Robinson RL, Grabner M, Palli SR, Faries D, Stephenson JJ.

J Psychosom Res. 2016 Jun;85:35-43. doi: 10.1016/j.jpsychores.2016.04.002. Epub 2016 Apr 13.

12.

Propensity score matching and subclassification in observational studies with multi-level treatments.

Yang S, Imbens GW, Cui Z, Faries DE, Kadziola Z.

Biometrics. 2016 Dec;72(4):1055-1065. doi: 10.1111/biom.12505. Epub 2016 Mar 17.

PMID:
26991040
13.

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.

Bae JP, Faries DE, Ernst FR, Lipkin C, Zhao Z, Moretz C, Lieu HD, Effron MB.

Am J Health Syst Pharm. 2016 Mar 15;73(6):395-403. doi: 10.2146/ajhp150065.

PMID:
26953284
14.

Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies.

Fu H, Zhou J, Faries DE.

Stat Med. 2016 Aug 30;35(19):3285-302. doi: 10.1002/sim.6920. Epub 2016 Feb 18.

PMID:
26892174
15.

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.

Jones ME, Andrews JS, Faries DE, Landry J, Xu J, Detke HC, Chhabra-Khanna R, McDonnell DP.

BMC Psychiatry. 2015 Nov 13;15:278. doi: 10.1186/s12888-015-0669-5.

16.

A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J.

Trials. 2015 Nov 3;16:495. doi: 10.1186/s13063-015-1023-4.

17.

Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy.

Bai X, Liu J, Li L, Faries D.

Pharm Stat. 2015 Nov-Dec;14(6):448-54. doi: 10.1002/pst.1719. Epub 2015 Oct 5.

PMID:
26436533
18.

Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries.

Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.

Alzheimers Dement. 2015 Aug;11(8):887-95. doi: 10.1016/j.jalz.2015.06.1889. Epub 2015 Jul 21.

19.

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study.

Dennehy EB, Robinson RL, Stephenson JJ, Faries D, Grabner M, Palli SR, Stauffer VL, Marangell LB.

Curr Med Res Opin. 2015 Jun;31(6):1165-77. doi: 10.1185/03007995.2015.1029893. Epub 2015 May 12.

PMID:
25879140
20.

The importance of unresolved fatigue in depression: costs and comorbidities.

Robinson RL, Stephenson JJ, Dennehy EB, Grabner M, Faries D, Palli SR, Swindle RW.

Psychosomatics. 2015 May-Jun;56(3):274-85. doi: 10.1016/j.psym.2014.08.003. Epub 2014 Aug 20.

21.

Propensity Score Matching and Subclassification With Multi-Level Treatments.

Kadziola Z, Yang S, Imbens GW, Cui Z, Faries DE.

Value Health. 2014 Nov;17(7):A587. doi: 10.1016/j.jval.2014.08.2002. Epub 2014 Oct 26. No abstract available.

22.

Evaluation of Estimators of Treatment Effect in Observational Studies.

Faries DE, Lipkovich I, Kadziola Z.

Value Health. 2014 Nov;17(7):A585-6. doi: 10.1016/j.jval.2014.08.1995. Epub 2014 Oct 26. No abstract available.

23.

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.

Bae JP, Faries DE, Ernst FR, Lipkin C, Zhao Z, Moretz C, Lieu HD, Effron MB.

Curr Med Res Opin. 2014 Nov;30(11):2207-16. doi: 10.1185/03007995.2014.941055. Epub 2014 Jul 18.

PMID:
25034466
24.

Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research.

Girman CJ, Faries D, Ryan P, Rotelli M, Belger M, Binkowitz B, O'Neill R; Drug Information Association CER Scientific Working Group.

J Comp Eff Res. 2014 May;3(3):259-70. doi: 10.2217/cer.14.16.

PMID:
24969153
25.

Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates.

Treuer T, Feng Q, Desaiah D, Altin M, Wu S, El-Shafei A, Serebryakova E, Gado M, Faries D.

Int J Clin Pract. 2014 Sep;68(9):1152-60. doi: 10.1111/ijcp.12437. Epub 2014 Apr 6.

PMID:
24703228
26.

Long-term evaluation of opioid treatment in fibromyalgia.

Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, Faries D, Wohlreich M, McCarberg B, Hann D.

Clin J Pain. 2015 Jan;31(1):7-13. doi: 10.1097/AJP.0000000000000079.

PMID:
24480913
27.

Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study.

Tanaka I, Sato M, Sugihara T, Faries DE, Nojiri S, Graham-Clarke P, Flynn JA, Burge RT.

J Osteoporos. 2013;2013:654218. doi: 10.1155/2013/654218. Epub 2013 Dec 12.

28.

Bayesian modeling of cost-effectiveness studies with unmeasured confounding: a simulation study.

Stamey JD, Beavers DP, Faries D, Price KL, Seaman JW Jr.

Pharm Stat. 2014 Jan-Feb;13(1):94-100. doi: 10.1002/pst.1604. Epub 2013 Nov 13.

PMID:
24446072
29.

Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder.

Faries DE, Chen Y, Lipkovich I, Zagar A, Liu X, Obenchain RL.

Int J Methods Psychiatr Res. 2013 Sep;22(3):185-94. doi: 10.1002/mpr.1390. Epub 2013 Aug 18.

PMID:
23956114
30.

Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study.

Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, Peng X, Hann D, Wohlreich M, McCarberg B.

Pain Med. 2013 Sep;14(9):1400-15. doi: 10.1111/pme.12168. Epub 2013 Jun 11.

31.

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.

Alatorre CI, Haynes V, Faries D, Upadhyaya H, Kelsey D.

Appl Health Econ Health Policy. 2013 Jun;11(3):305. doi: 10.1007/s40258-013-0024-2. No abstract available.

PMID:
23539190
32.

Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.

Faries D, Peng X, Pawaskar M, Price K, Stamey JD, Seaman JW Jr.

Value Health. 2013 Mar-Apr;16(2):259-66. doi: 10.1016/j.jval.2012.10.012. Epub 2013 Jan 23.

33.

Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.

Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, Wohlreich MM, Wu A.

Pain Pract. 2014 Jan;14(1):22-31. doi: 10.1111/papr.12044. Epub 2013 Mar 14.

PMID:
23489659
34.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

Ascher-Svanum H, Weiden P, Nyhuis AW, Faries DE, Stauffer V, Kollack-Walker S, Kinon BJ.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):84-90, 90A. doi: 10.3371/CSRP.ASWE.022213.

PMID:
23446198
35.

Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.

Cui Z, Faries DE, Shen W, Able SL, Novick D.

J Med Econ. 2013;16(5):623-32. doi: 10.3111/13696998.2013.778267. Epub 2013 Mar 5.

PMID:
23425292
36.

Comparing symptom response among antipsychotic medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2013 Feb;33(1):123-6. doi: 10.1097/01.jcp.0000426178.43831.ed. No abstract available.

PMID:
23288232
37.

A cross-validation of the provisional diagnostic instrument (PDI-4).

Faries DE, Houston JP, Sulcs EM, Swindle RW.

BMC Fam Pract. 2012 Oct 15;13:104. doi: 10.1186/1471-2296-13-104.

38.

The challenges of evaluating dose response in flexible-dose trials using marginal structural models.

Lipkovich I, Mallinckrodt CH, Faries DE.

Pharm Stat. 2012 Nov-Dec;11(6):485-93. doi: 10.1002/pst.1540. Epub 2012 Oct 12.

PMID:
23060290
39.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

40.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

41.

Association of blood glucose levels with in-hospital mortality and 30-day readmission in patients undergoing invasive cardiovascular surgery.

Lee LJ, Emons MF, Martin SA, Faries D, Bae J, Nathanson BH, Yu HT, Haidar T, Bode BW.

Curr Med Res Opin. 2012 Oct;28(10):1657-65. doi: 10.1185/03007995.2012.718268. Epub 2012 Sep 3.

PMID:
22867281
42.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D.

Psychiatry Res. 2012 Dec 30;200(2-3):835-42. doi: 10.1016/j.psychres.2012.05.005. Epub 2012 Jul 28.

PMID:
22841345
43.

Predictors of duloxetine adherence and persistence in patients with fibromyalgia.

Cui Z, Zhao Y, Novick D, Faries D.

J Pain Res. 2012;5:193-201. doi: 10.2147/JPR.S31800. Epub 2012 Jun 22.

44.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x. Epub 2012 Mar 8.

PMID:
22321776
45.

Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.

Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H.

Schizophr Res. 2012 May;137(1-3):141-6. doi: 10.1016/j.schres.2012.01.014. Epub 2012 Feb 7.

PMID:
22316567
46.

Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.

Liu X, Cui Z, Niu L, Faries DE, Ball T, Johnstone B.

Clin Ther. 2011 Nov;33(11):1726-38. doi: 10.1016/j.clinthera.2011.09.027. Epub 2011 Oct 22.

PMID:
22019345
47.

Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.

Cui Z, Faries DE, Gelwicks S, Novick D, Liu X.

J Med Econ. 2012;15(1):134-44. doi: 10.3111/13696998.2011.632043. Epub 2011 Nov 2.

PMID:
22014076
48.

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

Schizophr Res. 2011 Dec;133(1-3):42-6. doi: 10.1016/j.schres.2011.09.018. Epub 2011 Oct 14.

PMID:
22000938
49.

Predicting psychiatric hospital admission among adults with schizophrenia.

Olfson M, Ascher-Svanum H, Faries DE, Marcus SC.

Psychiatr Serv. 2011 Oct;62(10):1138-45. doi: 10.1176/ps.62.10.pss6210_1138.

PMID:
21969639
50.

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy.

Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, Kane JM.

Clinicoecon Outcomes Res. 2011;3:79-87. doi: 10.2147/CEOR.S16859. Epub 2011 Apr 20.

Supplemental Content

Loading ...
Support Center